ZA200500097B - Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow edema - Google Patents
Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow edema Download PDFInfo
- Publication number
- ZA200500097B ZA200500097B ZA200500097A ZA200500097A ZA200500097B ZA 200500097 B ZA200500097 B ZA 200500097B ZA 200500097 A ZA200500097 A ZA 200500097A ZA 200500097 A ZA200500097 A ZA 200500097A ZA 200500097 B ZA200500097 B ZA 200500097B
- Authority
- ZA
- South Africa
- Prior art keywords
- hydroxy
- treatment
- group
- production
- pharmaceutical agent
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 59
- 206010051763 Bone marrow oedema Diseases 0.000 title claims description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 201000010099 disease Diseases 0.000 title claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- 150000003815 prostacyclins Chemical class 0.000 title claims description 12
- 239000003814 drug Substances 0.000 title description 10
- 206010031264 Osteonecrosis Diseases 0.000 claims description 30
- 229960002240 iloprost Drugs 0.000 claims description 30
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 30
- 201000008482 osteoarthritis Diseases 0.000 claims description 20
- -1 hydroxymethylene group Chemical group 0.000 claims description 14
- 239000008177 pharmaceutical agent Substances 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001123 epoprostenol Drugs 0.000 claims description 5
- COTOHBYFKOEMEU-PDWIHATRSA-N (5e)-5-[(3as,4s,5r,6as)-5-hydroxy-4-[(3s)-3-hydroxynon-1-ynyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoic acid Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)CCCCCC)[C@H](O)C[C@@H]21 COTOHBYFKOEMEU-PDWIHATRSA-N 0.000 claims description 4
- OINUMRGCICIETD-CGKNXJIZSA-N 3-[(e)-[(3as,4r,5r,6as)-4-[(e,3s)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]methyl]benzoic acid Chemical compound C([C@H]1C[C@@H](O)[C@@H]([C@H]1C1)/C=C/[C@@H](O)C2CCCCC2)\C1=C/C1=CC=CC(C(O)=O)=C1 OINUMRGCICIETD-CGKNXJIZSA-N 0.000 claims description 4
- ZLJOKYGJNOQXDP-OZUBPDBUSA-N 3-[(z)-[(3ar,4r,5r,6as)-4-[(e,3s)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]methyl]benzoic acid Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@H]1C1)/C=C/[C@@H](O)C2CCCCC2)\C1=C/C1=CC=CC(C(O)=O)=C1 ZLJOKYGJNOQXDP-OZUBPDBUSA-N 0.000 claims description 4
- VKPYUUBEDXIQIB-QBPWRKFFSA-N Ciprostene Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@]21C VKPYUUBEDXIQIB-QBPWRKFFSA-N 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229960002890 beraprost Drugs 0.000 claims description 4
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims description 4
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 claims description 4
- 229950000634 cicaprost Drugs 0.000 claims description 4
- 229950009522 ciprostene Drugs 0.000 claims description 4
- 229950006939 naxaprostene Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- SRVNVLSGXFMMLE-UVZUILRGSA-M sodium;(5e)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(1e,3s)-3-hydroxy-5,9-dimethyldeca-1,8-dienyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoate Chemical compound [Na+].C1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CC(CCC=C(C)C)C)[C@H](O)C[C@@H]21 SRVNVLSGXFMMLE-UVZUILRGSA-M 0.000 claims description 4
- FNISYWNXCFSQFT-QUTHGGQZSA-M sodium;(5r)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(z,3s)-3-hydroxyoct-1-enyl]-4,5,6,6a-tetrahydro-3ah-cyclopenta[b]furan-3-yl]-5-fluoropentanoate Chemical compound [Na+].O1C=C([C@H](F)CCCC([O-])=O)[C@@H]2[C@@H](\C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 FNISYWNXCFSQFT-QUTHGGQZSA-M 0.000 claims description 4
- 229950002177 taprostene Drugs 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 claims 3
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 claims 3
- YZGQDNOIGFBYKF-UHFFFAOYSA-N Ethoxyacetic acid Chemical compound CCOCC(O)=O YZGQDNOIGFBYKF-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 description 53
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 210000003127 knee Anatomy 0.000 description 9
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 229960004380 tramadol Drugs 0.000 description 8
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- KZSSWXACMCYLBM-RMWNCEGRSA-N (5e)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 KZSSWXACMCYLBM-RMWNCEGRSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002636 symptomatic treatment Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010006002 Bone pain Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 125000004812 1-ethylethylene group Chemical group [H]C([H])([H])C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000030016 Avascular necrosis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000015854 Heliotropium curassavicum Nutrition 0.000 description 1
- 244000301682 Heliotropium curassavicum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000037234 cartilage building Effects 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Description
® ®
Use of Orally Available Prostacyclin Derivatives for the Production of a
Pharmaceutical Agent for Treating Diseases That are Associated with Bone Marrow
Edemas
The invention relates to the subject that is indicated in the claims, i.e., the use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas.
For osteonecrosis and recently also for osteoarthritis in the knee, a connection between the presence of a bone marrow edema and pain is assumed (Felson et al, Ann
Intern Med, 2001, 134(7); 541-593).
Osteonecrosis (syn.: aseptic necrosis, avascular necrosis, ischemic necrosis) is a common disease. In this case, pain is the indicating sign. In about two thirds of the patients, this pain occurs at rest. Osteonecrosis is often described as a transient process.
When the course proceeds spontaneously, in most cases what happens is a complete healing after 6 to 12 months. In this period, however, the patient is burdened by intense pain that is often not affected even by a commonly used pain therapy. The incidence rates of the progression of an early osteonecrosis up to the end stage with pronounced bone necroses are not known. Osteonecrosis is responsible for more than 10% of all joint replacement operations performed annually.
Osteoarthritis in the knee is a common disease that attacks about 11-15% of those over 65 years of age and is the most frequent cause of physical handicap in older humans.
® _ @
The main reason for physical limitations and visits to physicians is knee pain.
Osteoarthritis is defined as primarily non-inflammatory joint destruction that begins with cartilage degeneration in adults, later also affects common joint structures and progresses irreversibly. The overall course is generally progressive, but alternating in phases in terms of clinical acuity. In the final stage, knee replacement is necessary.
Osteonecrosis and osteoarthritis are most often manifested on hip and knee joints, but also on shoulder joints, wrists and ankles.
While in the treatment of osteonecrosis, surgical bone marrow decompression (perforation) with all its disadvantages such as in-patient stay and surgical intervention is performed as a means for alleviating pain, the treatment of osteoarthritis now exists only in symptomatic pain treatment and is inadequately effective. It usually comprises the permanent prescription of analgesics and/or antiphlogistic agents, combined with physiotherapy and weight reduction as well as optionally the intra-articular injection of anesthetics, corticoids or “cartilage-building/-replacing” substances. X-ray excitation radiation and acupuncture are also prescribed. Therapy of arthrosis is also limited here to date to a symptomatic treatment.
The established therapies are unsatisfactory both for osteonecrosis and for osteoarthritis because of the limitation to symptomatic treatment. In particular, the continued existence of dolorogenic mechanisms requires a long-term treatment that is associated with additional risks and costs. A causal treatment of pain with permanent freedom from pain is therefore especially desirable for osteoarthritis.
It is known that alleviation of pain in osteonecrosis can be achieved by a five-day intravenous infusion therapy with llomedin® (iloprost-trometamol) (Aigner et al., J Bone
® _ @
Joint Surg, 2001, 83(6): 855-858). The freedom from pain promptly reached with the reduction of bone marrow edema does not free the physician from close controls over an extended period, however, since the freedom from pain that is achieved masks a possible progression in a necrotic stage ofthe bone. Beyond the freedom from pain, treatment of necrotic lesions with the purpose of obtaining or restoring healthy bone tissue is therefore desirable.
The object was therefore to find a treatment of diseases that are associated with bone marrow edemas, especially osteonecrosis and osteoarthritis, that is not limited to only symptomatic treatment, i.e., combating pain, but rather also restores the structural integrity of the bone, and in addition to make available a pharmaceutical agent that can be taken over an extended period by the patient himself without the support of the physician. [t has now been found, surprisingly enough, that orally available prostacyclin derivatives, especially the cyclodextrin clathrates of the prostacyclin derivatives of general formula I vy“ > COOR' xX x : (J, -W-D-E-R? ® ® in which
R! means a hydrogen atom or a C,-C,o-alkyl radical,
A means a —CH,-CH,- group, a trans -CH=CH- group or a -C=C- group,
WwW means a free hydroxymethylene group, or a hydroxymethylene group that
® ® is functionally modified to form a hydroxy group, whereby the hydroxy group is in o- or B-position,
X,Y, independently of one another, mean a -CH,- group or an oxygen atom,
Zz means a hydrogen atom or a cyano group,
D means a straight-chain or branched, saturated C,-Cs-alkylene group,
E means a -C=C- group or a direct bond,
R? means a straight-chain or branched, saturated C,-Cs-alkyl group, rR’ means a free or functionally modified hydroxy group, and all optically active forms, racemates, diastereomers, diastereomer mixtures, clathrates thereof, and if R' has the meaning of a hydrogen atom, the salts thereof with physiologically compatible bases, achieve this object.
A 28-day treatment of patients with painful bone marrow edema by iloprost f3- cyclodextrin clathrate (iloprost oral) reduced not only the bone marrow edema but also restored the structural integrity, i.e., necrotic areas and lesions were healed. The alleviation of pain and the improved articulation could be observed even two months after the end of treatment. Treatment with orally available prostacyclin derivatives, especially with cyclodextrin clathrates of the prostacyclin denvatives of formula I, thus represents a novel therapy that not only suppresses the symptoms, i.€., the pain, but combats the causes of osteonecrosis and osteoarthritis and for the first time can also be clinical, studied independently.
This finding is all the more surprising in that earlier studies, such as, e.g., the placebo-controlled studies for treatment of severe ischemia of the legs, did not show
® ® iloprost B-cyclodextrin clathrate to have any effectiveness (Eur J Vasc Endovasc Surg, 2000, 20(4): 358-362). The effectiveness of the intravenous treatment with iloprost- trometamol, which is approved for treatment of the serious ischemia of the legs, thus could not be reproduced.
It is consequently not possible to predict that iloprost B-cyclodextrin clathrate will have an advantageous action in every case based on knowledge regarding intravenous iloprost-trometamol.
As alkyl group R', straight-chain or branched alkyl groups with 1-10 carbon atoms can be considered, such as, for example, methyl, ethyl, propyl, 2-methylethyl, n- butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl (tert-butyl), hexyl, heptyl, octyl, nonyl or decyl.
Alkyl group R! can also be substituted. As substituents, for example, fluorine, chlorine or bromine atoms, phenyl, dimethylamino, diethylamino, methoxy, and ethoxy can be mentioned.
As alkyl group RY alkyl groups with 1-4 carbon atoms are preferred.
Alkyl group R? is straight-chain or branched; by way of example, reference can be made to the chain length that corresponds to radicals that are mentioned for R!, and alkyl group R? has 1-7 carbon atoms, preferably 1-3 carbon atoms, especially preferably 1-2.
The hydroxy groups in R® and W can be functionally modified. Thus, an esterification or etherification is meant. The thus obtained ethers and/or acyl radicals are radicals that are known to one skilled in the art.
®
Ether radicals are, e.g., tetrahydropyranyl, tetrahydrofuranyl, methoxymethyl, methoxyethyl, ethoxyethyl, silyl ether, such as, e.g, trimethylsilyl, dimethyl-tert- butylsilyl, or triphenylsilyl.
Acyl radicals can be, for example, acetyl, propionyl, butyryl, or benzoyl.
X preferably has the meaning of a CH; group.
Z preferably means a hydrogen atom.
As alkylene group D, straight-chain or branched saturated alkylene groups with 1- carbon atoms are considered. For example, methylene, ethylene, propylene, 1- methylethylene, butylene, 1-methyl-propylene, 2-methylpropylene, pentylene, 1- methylbutylene, and 1-ethylethylene can be mentioned. A branched alkylene group with 3 carbon atoms is preferred.
If R! means a hydrogen atom, the compounds of formula I can also be present as salts of physiologically compatible bases.
Both inorganic and organic bases are suitable for salt formation. For example, alkali hydroxides such as sodium or potassium hydroxide; alkaline-earth hydroxides such as calcium hydroxide, or ammonia; and amines such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, or tris-(hydroxymethyl)methylamine can be mentioned.
Prostacyclin derivatives are orally available as defined by the invention at the time when they can be used according to suitable formulation for oral administration.
In addition, especially a- or B-cyclodextrin clathrates or hydroxylated forms thereof are suitable.
®
Especially suitable for the treatment of diseases that are associated with bone marrow edemas, especially for the treatment of osteonecroses and osteoarthritis, are also the following known prostacyclin derivatives of general formula I that are formulated for oral administration: cicaprost (5-{(E)-(1S,5S,6S,7R)-7-hydroxy-6-[(3S,4S)-3-hydroxy-4- methyl-1,6-nonadiinyl]-bicyclo[3.3.0]-oct-3-ylidene} -3-oxapentanoic acid), epoprostenol ((5Z,90,13E,15S)-6,9-epoxy-11,15-dihydroxy-prosta-5,13-dienoic- 1-acid), beraprost (EP 0084 856), ciprostene, taprostene, naxaprostene, CS 570, SC-39902, FCE-22509,
OP 41483 and RS 93427.
The B-cyclodextrin clathrate of itoprost, (5-{(1S,5S,6R,7R)-7-hydroxy-6-{(E)- (3R,4RS)-3-hydroxy-4-methyl-oct-1-en-6-inyl]-bicyclo[3.3.0]octan-3-ylidene} pentanoic acid)-B-cyclodextrin clathrate, is especially suitable. Within a treatment of 28 days, a significant improvement of the pain that is immediately noticeable to the patients and that is associated with a significant reduction of the bone marrow edema and a healing of necroses takes place.
The use of iloprost-B-cyclodextrin clathrate for the production of a pharmaceutical agent for treating osteonecrosis and osteoarthritis is therefore a preferred subject of the invention. [loprost is a prostacyclin analog that 1s known from EP 11 591 and can be produced by methods disclosed therein. The nomenclature name for iloprost is (5- {(1S,5S,6R,7R)-7-hydroxy-6-[(E)-(3R,4RS)-3-hydroxy-4-methyl-oct-1-en-6-inyl]- bicyclo[3.3.0]Joctan-3-ylidene} pentanoic acid). [loprost-B-cyclodextrin-clathrate 1s known from EP 259468 and can be produced according to methods that are disclosed there.
®
It is known from EP 1 016 408 that prostanoids are C-C chemokine-production inhibitors. For the bone marrow edema, the mechanisms that are disclosed there are not relevant according to present knowledge.
With respect to conventional methods for treating osteonecroses and osteoarthritis, avoiding a cost-intensive in-patient stay, cutting down on surgical interventions (perforation, especially for osteonecroses), reducing the necessity for implantation of artificial joints, avoiding costs for treating side effects of conventional pain medications, reducing the morbidity, shortening the disability time, improving the quality of life and reducing the number of visits to the doctor are significant advantages.
In particular, the oral administration makes possible a longer-term medication with a causal therapy stock that the patients can take largely independently of any medical support.
The suitable dose range for the treatment of osteonecrosis and osteoarthritis is between 50 pg/day and 350 pg/day, preferably between 100 pg/day and 300 pg/day or between 150 pg/day and 350 pg/day, whereby these amounts can be distributed with several individual dosages. A healing of the bone necroses can be achieved within a few weeks.
Figure 1: Significant abatement of the resting pain under oral iloprost treatment measured by means of a 100 mm visual analog scale with end points 0 = no pain and
® ® 100 = intolerable pain. The alleviation of pain is already considerable after 3 days of treatment. Almost complete freedom from pain is achieved after a 28-day treatment and persists over a period of 2 months without therapy.
Data as average values + SEM. p-Values as a comparison of the corresponding times with the starting value, with *p < 0.05 and **p < 0.001 (ANOVA)
Figure 2: Significant abatement in pain afier defined stress measured by means of a 100 mm visual analog scale with end points 0 = no pain and 100 = intolerable pain.
The alleviation of pain is already considerable after 3 days of treatment. Almost complete freedom from pain is achieved after a 28-day treatment and persists over a period of 2 months without therapy.
Data as average values + SEM. p-Values as a comparison of the corresponding times with the starting value, with *p < 0.05 and **p < 0.001 (ANOVA)
Figure 3: Significant increase of the knee activity score according to Larson (maximum score 100) after a 14-day treatment. The improvement persists over a period of 2 months without therapy.
Data as average values + SEM. p-Values as a comparison of the corresponding times with the starting value, with *p < 0.05 and **p < 0.001 (ANOVA)
Figure 4: Case example of a patient with complete degeneration of a diffused bone marrow edema in the early stages of osteonecrosis. The control-MRI study was carried out 2 months after the 28-day treatment with oral tloprost was completed.
_ ®
Figure 5: Same pronounced abatement in resting pain when administered in a double- blind trial of oral iloprost treatment and Tramadol® treatment measured by means of a 100 mm visual analog scale with end points 0 =no pain and 100 = intolerable pain.
Almost complete freedom from pain is achieved after 28 days of treatment and persists over a period of 2 months without therapy.
Data as average values + SEM. p-Values for comparing the two treatments confirm their equivalence (Hodges-Lehmann-Schitzer and Wilcoxon Test).
Figure 6: Same pronounced abatement in activity-related pain under double-blind administration of oral iloprost treatment and Tramadol® treatment measured by means of a 100 mm visual analog scale with the end points 0 = no pain and 100 = intolerable pain.
A considerable reduction in pain is achieved after 28 days of treatment and persists over a period of 2 months without therapy.
Data as average values + SEM. p-Values for comparing the two treatments confirm their equivalence (Hodges-Lehmann-Schitzer and Wilcoxon Test).
Figure 7. Same pronounced increase in the knee activity score according to Larson (maximum score 100) under double-blind administration of oral iloprost treatment and
Tramadol® treatment. The improvement persists over a period of 2 months without therapy.
Data as average values + SEM. p-Values for comparing the two treatments confirm their equivalence (Hodges-Lehmann-Schitzer and Wilcoxon Test).
Figure 8: Oral iloprost produced a complete degeneration of the bone marrow edema in at least one affected bone in 53% of patients, while this was the case in only 19% of the patients under Tramadol®.
This difference was statistically significant (p = 0.0336, Fisher’s Exact Test)
® _
Experiments
Pilot Studies
For the action of oral iloprost on the bone marrow edema and pain, an open pilot study with 19 patients with osteonecrosis of the knee was performed in the 1.
Orthopidische Abteilung des Orthopadischen Spital Wien-Speising {1¥ Orthopedic
Department of the Orthopedic Hospital of Vienna-Speising], Prim. Dr. F. LandsiedV/Dr.
N. Aigner, in the period from March to November 2001.
Before the beginning of the study, all patients gave their written consent to participate in the study after they were informed extensively orally and in writing on the type, purpose and course of the study.
Patients of both sexes with resting pain because of an osteonecrosis were included in the study if the following criteria were met: eo Age between 19 and 60 years, e Bone marrow edema found by means of MRT according to specified criteria, ¢ Normal x-ray finding without signs of osteoarthritis and no subchondral attack of the bone.
The treatment was carried out with iloprost capsules that were packaged and identified according to valid GLP rules. Each capsule contained 50 ug of iloprost.
During the first three days of treatment, iloprost was administered in a dosage of 3x50 ug of iloprost during the day, which starting on day 4 could be increased individually up to a maximum dose of 3x100 ng of iloprost during the day:
® ® e To increase the success of the therapy (alleviation of pain), this dosage could be carried out both by increasing the individual dose (maximum: 3x100 pg of iloprost during the day) and by shortening the intake-free interval (minimum: 2 hours, i.e., 6x50 ug of iloprost during the day). * Inthe case of poor tolerance, the dosage could always be reduced to a minimum dose of 2x50 ug of iloprost during the day.
The treatment period was one month. Previously administered pain-relieving medications should be discontinued before the beginning of the study.
All medications for the treatment of accompanying diseases were able to be maintained at the usual dosages.
The clinical action of the treatment was determined based on the following parameters: « Evaluation of the intensity of the resting pain and the activity-related pain by the patient based on a 100 mm scale, whereby O means “no pain,” and 100 means “intolerable pain.” The stress was defined as climbing and descending a specified set of stairs. e Evaluation of the functional condition of the knee by means of Larson
SCOres. e Evaluation of the bone marrow edema by means of MRT.
As safety parameters, undesirable events and side effects were detected. Known side effects of iloprost are symptoms such as headache, reddening of the face, nausea, vomiting and diarrhea.
The course of the study was presented as follows:
Prelimi- Treatment Follow- naryTest up Test
Visit 1 0 3 4 o 6 7
Da ay | Day | Da ay | Day | Da
INT | | R56 | ve
Dechartionorconen | @ | | 1 inclusion and exclusion ters | @
Cacho | @ | | | [| | | I
Physical test ® | [ [ [ I | [
Pregancytest. ~~ | @ [| | | | [@]|@®@]
Polling fo side eects [ele [e[elel
LasonScre ~~~ | @ [00/00/00 O i |e e[elelelelele intensity
MRT ee | | | [ [ [
X-ray image of the affected knee 1) The study could take place over six weeks.
As a result of a 28-day treatment with oral iloprost, freedom from pain at rest and during activity was almost achieved in patients with osteonecrosis, the majority of whom, before the beginning of the study, had unsuccessfully taken a number of other medication combinations over several weeks. The action on the pain could already be detected after a 3-day treatment and persisted 2 months afler the end of the treatment. With the reduction of pain, a complete degeneration of bone marrow edema was noted in MR control images in 44% of the patients.
Double-Blind Comparison Studies
To confirm the action of oral iloprost on the bone marrow edema and the pain, a random, double-blind comparison study was performed on the opiate Tramadol® in 41
® ® patients with osteonecrosis or osteoarthritis of the knee in the period from March 2001 to
November 2002 according to the GCP guidelines.
Before the beginning of the study, all patients gave their written consent to participate in the study afler they were informed extensively orally and in writing on the type, purpose and course of the study.
Patients of both sexes with resting pain because of an osteonecrosis or osteoarthritis were included in the study if the following criteria were met: eo Age between 19 and 60 years, e Bone marrow edema found by means of MRT according to specified criteria.
The treatment was carried out either with iloprost capsules or with outwardly indistinguishable Tramadol capsules that were packaged and characterized according to valid GLP rules. Each capsule contained either 50 ug of iloprost or 50 mg of Tramadol®.
During the first three days of treatment, the study medication was administered in a dosage of 3x1 capsules during the day, which starting on day 4 could be increased individually to increase the success of the therapy (alleviation of pain) up to a maximum dose of 3x2 capsules during the day. In the case of poor tolerance, the dosage could always be reduced to a minimum dose of 2x1 capsules during the day.
The treatment period was one month, followed by a follow-up observation period of two months during which no treatment was given. Previously administered pain- relieving medications should be discontinued before the beginning of the study.
All medications for the treatment of accompanying diseases were able to be maintained at the usual dosages.
®
The clinical action of the treatment was determined based on the following parameters: » Evaluation of the intensity of the resting pain and the activity-related pain by the patient based on a 100 mm scale, whereby 0 means “no pain,” and 100 means “intolerable pain.” ¢ Evaluation of the functional condition of the knee by means of Larson scores. e Evaluation of the bone marrow edema by means of MRT.
As safety parameters, undesirable events and side effects were detected. Known side effects of iloprost are symptoms such as headache, reddening of the face, nausea, vomiting and diarrhea.
® ®
The course of the study was presented as follows:
Preliminary Treatmentl) Alterna-| Follow-
Test tive up
Therapy | Test!)
Screen {Basel 1 | 2 | 3 | 4 |gpy|DaiDaflgglTs -ing | -line y y 14| 5
Visit 3)
Da{Da|{ Da | Da | Da Da | Da y3|ly7\ y |v |Y y |v 14 | 21 | 28 56 | 84 [Declaration ofconsent |@ [| [ [ [| | | [
Inclusion and exclusion nena oo | [LLL] treme (® | LLL [Employmentstaws |@ [| [ [| | [ [ (Workdisabiliy |@ [@ |@@@ @ @ 0 @[@ @
Physicaltest |@ [| | | | | @] @] [@ eT eee 6
Randomizaton | [(@ | | | © [ [ [| | [
Dispensing of research ctor | jo | lelele]
Withdrawal of unused mesmn || | [eeele]
Dose/dosage adjustment, oon =| | eleeo| (@@
Polling forsideefecs | | OO @/@] | |@ @]
Blood samples (hematology, clinical chemistry), urinalysis Cl of jo
Preliminary and mpc [@ | [@]0[0 [00 [0 [00]
Tasonscoe | [@ [00 [@ [0 [@] [0 [00]
Patient evaluation of the ranma | @|@/eje@ eee oe. ver le [| TT [| | |@] en FUN AEN EE ERE knee
1) Visits outside of the planned time guide could be carried out both during treatment and during the follow-up test. 2) End of research medication or early stopping of the research medication. 3) End of alternative therapy or early stopping of alternative therapy. 4) Visit 6 took place on day 56 or after 4 treatment-{ree weeks. 5) Visit 7 took place on day 84 or after 8 treatment-free weeks. 6) Urine-strip test. 7) The study can take place within 6 weeks of the baseline.
In patients with osteonecrosis or osteoarthritis, oral iloprost produced a degeneration of the bone marrow edema in 53% of patients, while this was the case in only 19% of the patients under Tramadol®. This difference was statistically significant (p = 0.0336, Fisher’s Exact Test). This effect coincided with a significant alleviation of pain as also shown in the pilot study. Moreover, only with iloprost therapy was a reduction in subchrondral lesions noted and thus a reference to the restoration of structural integrity was provided.
Claims (10)
1. Use of orally available prostacyclin derivatives of general formula I vy” > CooR! X xX 3 . -W-D-E-R? ® 00 in which R! means a hydrogen atom or a C,-C,-alkyl radical, A means a -CH,-CH,- group, a trans -CH=CH- group or a -C=C- group, Ww means a free hydroxymethylene group, or a hydroxymethylene group that is functionally modified to form a hydroxy group, whereby the hydroxy group is in a- or B-position, X,Y, independently of one another, mean a —CH,- group or an oxygen atom, Zz means a hydrogen atom or a cyano group, D means a straight-chain or branched, saturated C,-Cs-alkylene group, E means a -C=C- group or a direct bond, R? means a straight-chain or branched, saturated C,-C;-alkyl group, rR’ means a free or functionally modified hydroxy group, and all optically active forms, racemates, diastereomers, diastereomer mixtures, clathrates thereof,
® and if R! has the meaning of a hydrogen atom, the salts thereof with physiologically compatible bases, for the production of a pharmaceutical agent for the treatment of diseases that are associated with bone marrow edemas.
2. Use according to claim 1, characterized in that the prostacyclin derivatives of formula [ are present as cyclodextrin clathrate.
3. Use of orally available prostacyclin derivatives according to claim 1 or 2 for the production of a pharmaceutical agent for the treatment of osteonecroses.
4. Use of orally available prostacyclin derivatives according to claim 1 or 2 for the production of a pharmaceutical agent for the treatment of osteoarthritis.
5. Use of orally available iloprost (5-{(18S,5S,6R,7R)-7-hydroxy-6-[(E)- (3R,4RS)-3-hydroxy-4-methyl-oct-1-en-6-inyl}-bicyclo[3.3.0]octan-3- ylidene} pentanoic acid), cicaprost (5-{(E)-(1S,5S,6S,7R)-7-hydroxy-6- [(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiinyl]-bicyclo[3.3.0]-oct-3-ylidene} - 3-oxapentanoic acid), epoprostenol ((5Z,9a,13E,15S)-6,9-epoxy-11,15- dihydroxy-prosta-5,13-dienoic-1-acid), beraprost (TRK 100), ciprostene, taprostene, naxaprostene, CS 570, SC-39902, FCE-22509, OP 41483 or RS 93427 according to claim 1 for the production of a pharmaceutical agent for the treatment of diseases that are associated with bone marrow edemas.
6. Use of orally available iloprost (5-{(1S,5S,6R,7R)-7-hydroxy-6-{(E)- (3R,4RS)-3-hydroxy-4-methyl-oct-1-en-6-inyl]-bicyclo[3.3.0]Joctan-3- ylidene}pentanoic acid), cicaprost (5-{(E)-(1S,5S,6S,7R)-7-hydroxy-6- [(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiinyl]-bicyclo[3.3.0]-oct-3-ylidene} -
® 3-oxapentanoic acid), epoprostenol ((5Z,9«,13E,155)-6,9-epoxy-11,15- dihydroxy-prosta-5,13-dienoic-1-acid), beraprost (TRK 100), ciprostene, taprostene, naxaprostene, CS 570, SC-39902, FCE-22509, OP 41483 or RS 93427 according to claim 2 for the production of a pharmaceutical agent for the treatment of osteonecroses.
7. Use of orally available iloprost (5-{(1S,5S,6R,7R)-7-hydroxy-6-[(E)- (3R,4RS)-3-hydroxy-4-methyl-oct-1-en-6-inyl]-bicyclo[3.3.0]octan-3- ylidene} pentanoic acid), cicaprost (5-{(E)-(1S,5S,6S,7R)-7-hydroxy-6- [(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiinyl]-bicyclo[3.3.0]-oct-3-ylidene} - 3-oxapentanoic acid), epoprostenol ((5Z,9«,13E,15S)-6,9-epoxy-11,15- dihydroxy-prosta-5,13-dienoic-1-acid), beraprost (TRK 100), ciprostene, taprostene, naxaprostene, CS 570, SC-39902, FCE-22509, OP 41483 or RS 93427 according to claim 3 for the production of a pharmaceutical agent for the treatment of osteoarthritis.
8. Use of iloprost-p-cyclodextrin-clathrate according to claim 1 for the production of a pharmaceutical agent for the treatment of diseases that are associated with bone marrow edemas.
9. Use ofiloprost-B-cyclodextrin-clathrate according to claim 2 for the - production of a pharmaceutical agent for treating osteonecrosis.
10. Use of tloprost-B-cyclodextrin-clathrate according to claim 3 for the production of a pharmaceutical agent for the treatment of osteoarthritis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10225551A DE10225551A1 (en) | 2002-06-06 | 2002-06-06 | Use of orally available prostacyclin derivatives for the manufacture of a medicament for the treatment of diseases associated with bone marrow edema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200500097B true ZA200500097B (en) | 2006-06-28 |
Family
ID=29594336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200500097A ZA200500097B (en) | 2002-06-06 | 2005-01-05 | Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow edema |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1515728A2 (en) |
| JP (1) | JP2005536476A (en) |
| KR (1) | KR20050007591A (en) |
| CN (1) | CN1658882A (en) |
| AU (1) | AU2003236715A1 (en) |
| CA (1) | CA2488861A1 (en) |
| DE (1) | DE10225551A1 (en) |
| WO (1) | WO2003103681A2 (en) |
| ZA (1) | ZA200500097B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5415771B2 (en) * | 2006-02-03 | 2014-02-12 | アクテリオン ワン エスエー | Novel epoprostenol formulation and method for producing the same |
| TWI520740B (en) * | 2011-02-02 | 2016-02-11 | 模範健康科技私人企業有限公司 | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides |
| EP3675909B1 (en) * | 2017-08-31 | 2023-10-18 | Charité Universitätsmedizin Berlin | Immunmodulation for prevention of poor healing of musculoskeletal injuries in compromised patients |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3608088C2 (en) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmaceutical preparations containing cyclodextrin clathrates of carbacyclin derivatives |
| DE59305822D1 (en) * | 1992-08-07 | 1997-04-17 | Schering Ag | USE OF PROSTANDERIVATIVES FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING CHRONIC POLYARTHRITIS |
| WO1999013880A1 (en) * | 1997-09-16 | 1999-03-25 | Toray Industries, Inc. | C-c chemokine production inhibitor |
| AU2002212996A1 (en) * | 2000-09-28 | 2002-04-08 | Non-Invasive Monitoring Systems, Inc. | External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention |
-
2002
- 2002-06-06 DE DE10225551A patent/DE10225551A1/en not_active Ceased
-
2003
- 2003-06-05 AU AU2003236715A patent/AU2003236715A1/en not_active Abandoned
- 2003-06-05 CA CA002488861A patent/CA2488861A1/en not_active Abandoned
- 2003-06-05 EP EP03735573A patent/EP1515728A2/en not_active Withdrawn
- 2003-06-05 WO PCT/EP2003/005990 patent/WO2003103681A2/en not_active Application Discontinuation
- 2003-06-05 JP JP2004510800A patent/JP2005536476A/en active Pending
- 2003-06-05 CN CN038129760A patent/CN1658882A/en active Pending
- 2003-06-05 KR KR10-2004-7019813A patent/KR20050007591A/en not_active Application Discontinuation
-
2005
- 2005-01-05 ZA ZA200500097A patent/ZA200500097B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003103681A3 (en) | 2004-03-25 |
| CN1658882A (en) | 2005-08-24 |
| CA2488861A1 (en) | 2003-12-18 |
| WO2003103681A2 (en) | 2003-12-18 |
| JP2005536476A (en) | 2005-12-02 |
| EP1515728A2 (en) | 2005-03-23 |
| DE10225551A1 (en) | 2003-12-24 |
| KR20050007591A (en) | 2005-01-19 |
| AU2003236715A1 (en) | 2003-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2166940C2 (en) | Method for reducing bone tissue losses, treating osteoporosis and applying a compound | |
| JP3623962B2 (en) | Pharmaceutical composition for intranasal administration of hydroxocobalamin | |
| US9044452B2 (en) | Use of resiniferatoxin (RTX) for producing an agent for treating joint pains and method for applying said agent | |
| KR100654653B1 (en) | Remedies for diseases in association with decrease in bone mass | |
| JPH09504543A (en) | Cataract prevention methods and preventive measures | |
| EP0980245B1 (en) | Use of misoprostol or/and misoprostol acid for the treatment of erectile dysfunction | |
| AU1059601A (en) | Pharmaceutical compositions and preparations for treatment of metabolic bone disease | |
| CA2592086A1 (en) | Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller | |
| JP2008525504A5 (en) | ||
| US8703741B2 (en) | Method of treating articular pain using a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan | |
| CA1306699C (en) | Fervescence composition containing 15-keto-pges | |
| GB2330307A (en) | EP4 Receptor antagonists as bone resorption inhibitors | |
| US20050101673A1 (en) | Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas | |
| ZA200500097B (en) | Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow edema | |
| US5925625A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| KR100385697B1 (en) | Bone-Weight Synthetic Composition Including Alpadronate | |
| EP0737185B1 (en) | 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl] 3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof | |
| NZ308935A (en) | Use of Alendronate for the prevention of osteoporosis | |
| EP3035925A1 (en) | Method for treating neuropathic pain | |
| CA2219354A1 (en) | Prevention of tooth loss by the administration of alendronate or its salts | |
| JPH0753388A (en) | Bone metabolism improver | |
| EP1107762B1 (en) | Use of misoprostol or/and misoprostol acid for preparing drug in order to cure sexual dysfunction in women | |
| JP2002538105A (en) | Use of a non-naturally occurring EP1 selective agonist for increasing bone volume | |
| NO316424B1 (en) | Use of prostate derivatives for the manufacture of drugs for the treatment of bacterial infections | |
| JP2001131073A (en) | Ache-treating agent |